Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, has appointed Nadia Agopyan, Ph.D., RAC as vice president of Regulatory Affairs. 

Dr. Agopyan joins the company from Kite Pharma, a subsidiary of Gilead Sciences, where she served as director of Regulatory Affairs, Global Regulatory Lead. In this role, she was responsible for overseeing the global marketing authorization and lifecycle management of the YESCARTA franchise, defining the global regulatory strategies for CAR T cell products in lymphoma/leukemia, and overseeing clinical programs from Phase 1-4 development and operational aspects of global regulatory submissions. Previously, she served as Global Regulatory Lead at Baxter Biosciences leading Vonvendi (recombinant von Willebrand Factor) approval/launch, senior director Regulatory Affairs at Ambit Biosciences, and director Regulatory Affairs at Cougar Biotechnology, a unit of Johnson and Johnson Ortho Biotech Oncology.

“We are pleased to welcome a professional of Nadia’s caliber and senior leadership experience to Marker,” said Peter L. Hoang, President & CEO of Marker. “With more than 15 years of industry knowledge in regulatory affairs and clinical development, Nadia will be instrumental in helping shape our regulatory strategy as we prepare to initiate the first Marker-sponsored trial with MultiTAA therapy in patients with post-transplant acute myeloid leukemia.”